Table 2.
Chloroquine | Quinine | Amodiquine | Mefloquine | Artemether | LUM | S-P | Cotrim* | |
---|---|---|---|---|---|---|---|---|
AZT | − | − | − | − | − | − | − | − |
3TC | − | − | − | − | − | − | − | − |
d4T | − | − | − | − | − | − | − | − |
ABC | − | − | − | − | − | − | − | − |
ddI | − | − | − | − | − | − | − | − |
FTC | − | − | − | − | − | − | − | − |
TDF | − | − | − | − | − | − | − | − |
NVP | NA | NA | + | NA | + | + | NA | NA |
EFV | NA | NA | + | NA | + | + | NA | NA |
LPV | + | NA | NA | NA | NA | + | NA | NA |
ATV | NA | NA | NA | NA | NA | + | NA | NA |
SQV | NA | NA | NA | NA | NA | + | NA | NA |
IDV | NA | NA | NA | NA | NA | + | NA | NA |
Cotrimoxazole is not recommended for treatment or prophylaxis of malaria in the general population, which is included because it has been recommended for such purpose in HIV + individuals
Abbreviations: Cotrim, cotrimoxazole (sulphamethoxazole-trimethoprim); S-P, sulphadoxine-pyrimethamine; LUM, lumefantrine; AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ABC, abacavir; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; NVP, nevirapine; EFV, efavirenz; LPV, lopinavir; ATV, atazanavir; SQV, saquinavir; IDV, indinavir
− No demonstrable interaction or clinically significant interaction is unlikely
+ Documented interactions or potential for interaction is high
NA No appreciable clinical data available or data completely lacking